In a randomized phase II study of patients with advanced treatment-naïve NSCLC, disease in those with squamous cell carcinoma responded to the combination of paclitaxel, carboplatin and an anti-IGF-1R antibody (CP-751,871) better than those with other histological subtypes [22]. Here, IGF1R is linked to squamous cell carcinoma.